Schroder Investment Management Group Decreases Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Schroder Investment Management Group cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 16.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,808 shares of the medical equipment provider’s stock after selling 3,018 shares during the period. Schroder Investment Management Group’s holdings in Hologic were worth $1,142,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of HOLX. Victory Capital Management Inc. raised its stake in shares of Hologic by 0.5% during the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after buying an additional 24,358 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Hologic by 3.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after acquiring an additional 129,035 shares during the last quarter. Boston Partners raised its position in Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after purchasing an additional 544,889 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $133,414,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

HOLX stock opened at $61.27 on Tuesday. The company has a market cap of $13.75 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average price of $64.07 and a two-hundred day moving average price of $72.37. Hologic, Inc. has a 12-month low of $59.06 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Morgan Stanley reduced their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Citigroup dropped their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Finally, Royal Bank of Canada lowered their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.